Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vivek Subbiah has been appointed as the inaugural associate director for drug development and precision oncology at the Stanford Cancer Institute, with a planned start date in spring 2026. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Patricio M. Polanco, a surgical oncologist specializing in hepato-pancreato-biliary malignancies and minimally invasive and robotic liver and pancreas surgery, has joined Atrium Health as division chief of surgical oncology, surgeon-in-chief for Atrium Health Levine Cancer in Charlotte, North Carolina and inaugural Richard L. White Jr. Endowed Professor of Surgery at Wake Forest University School of Medicine. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login